Isaac Kobrin, M.D. Joins IMMUNE Pharmaceuticals' Board of Directors

HERZLIYA, Israel and NEW YORK, Nov. 29, 2011 /PRNewswire/ -- IMMUNE Pharmaceuticals, an emerging leader in the development of antibody based therapeutics for the treatment of inflammatory diseases and cancer, today announced the appointment of Isaac Kobrin, M.D. to its Board of Directors.  Dr. Kobrin will play a key role in helping build IMMUNE into a leading global biopharmaceutical company.

"We are thrilled and honored to welcome Isaac to the IMMUNE Board of Directors," said Dr. Daniel Teper, Founder, Chairman of the Board and Chief Executive Officer of IMMUNE Pharmaceuticals.  "Dr. Kobrin has an exceptional track record in drug development and commercialization; he is a true entrepreneur and company builder."

Dr. Kobrin led worldwide clinical programs from Phase I development through to regulatory approval and marketing launch for several major drugs.  He spent 10 years at Roche Global Headquarters in Basel, Switzerland and in Nutley, New Jersey, USA.  He then joined Actelion Pharmaceuticals in September 1999 to build and lead its clinical development department.  Dr. Kobrin held the position of Head of Clinical Development till 2009, when he was appointed to Chief Medical Officer and Chairman of the Strategic and Portfolio Board.  At Actelion, Dr. Kobrin led the development of several large programs, which supported a successful initial public offering on the Swiss Stock Exchange Moreover, under Dr Kobrin's leadership Tracleer, the flagship drug of Actelion reached regulatory approval world-wide, which was the bases for Actelion's growth to become the largest European-based global biotechnology company.

Dr. Kobrin graduated from and completed his residency at Hadassah Medical School in Jerusalem.  He is Board certified in Internal Medicine and completed a Fulbright Fellowship at the Ochsner Foundation in New Orleans, Louisiana, USA.  Dr. Kobrin was a Senior Lecturer and the Director of Pre Hypertension Research Unit at Mount Scopus Hadassah Hospital prior to joining Roche in 1989.

"I am extremely proud to have been chosen as a member of the Board of Directors of Immune Pharmaceuticals.  I am very impressed with the Company's research and development platforms which include Bertilimumab, a first-in-class fully human monoclonal antibody against eotaxin-1 ready to enter phase II in multiple indications and the innovative Antibody Drug Conjugate technology of NanoMabs that could significantly improve the efficacy and safety of anti-cancer and anti-inflammatory drugs. Both technologies could become meaningful therapeutic solutions and result in long-term business success. I look forward to helping and supporting Immune in their development and strategic plans together with the other board members and the Management team," said Dr Kobrin.

About IMMUNE Pharmaceuticals
IMMUNE Pharmaceuticals is an Israel and U.S. based biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing significant unmet medical needs in the treatment of inflammatory diseases and cancer. IMMUNE Pharmaceuticals has built a robust pipeline of clinical and pre-clinical candidates based on novel targets and best-in-class antibody technologies. IMMUNE licensed worldwide rights for systemic indications of Bertilimumab from iCo Therapeutics (TSX:ICO) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to Bertilimumab in 2006 from MedImmune Limited (formerly known as Cambridge Antibody Technology Limited), the Global Biologics Arm of AstraZeneca. IMMUNE also licensed from Yissum, the Technology Transfer Company of Hebrew University of Jerusalem, an Antibody Drug Conjugate platform (NanoMAbs), which allows to deliver micro-doses of chemotherapeutics into target cells.

For more information, visit the Company website at: www.immunepharmaceuticals.com
 
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based IMMUNE Pharmaceuticals current beliefs as well as assumptions made by and information currently available to IMMUNE Pharmaceuticals and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties; actual events may differ materially from current expectations. IMMUNE Pharmaceuticals disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Mr. Serge Goldner, Chief Financial Officer, IMMUNE Pharmaceuticals, +972505203100 [email protected]
Ms Justyna Figiel, Media and Investor Relations, IMMUNE Pharmaceuticals,  347-437-0218 [email protected]
Mrs. Marcy Nanus, Vice President, The Trout Group, LLC., 646-378-2927, [email protected]

SOURCE IMMUNE Pharmaceuticals